Want to see HK:2196 full AI Analyst Report?

Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

5 Followers

2196 Stock Chart & Stats

HK$16.07

HK$0.13(0.81%)

At close: Jul 27 4:00 PM EDT

HK$16.07

HK$0.13(0.81%)

Day’s Range― - ―

52-Week RangeHK$14.90 - HK$29.00

Previous CloseN/A

Volume1.85M

Average Volume (3M)8.63M

Market Cap

HK$64.43B

Enterprise ValueHK$84.21K

Total Cash (Recent Filing)HK$15.29B

Total Debt (Recent Filing)HK$31.86B

Price to Earnings (P/E)17.2

Beta1.13

Next Earnings

Aug 26, 2026

EPS Estimate

0.41

Next Dividend Ex-DateN/A

Dividend Yield2.8%

Share Statistics

EPS (TTM)1.61

Shares Outstanding551,940,500

10 Day Avg. Volume5,166,409

30 Day Avg. Volume8,626,817

Financial Highlights & Ratios

PEG Ratio0.74

Price to Book (P/B)0.95

Price to Sales (P/S)1.15

P/FCF Ratio60.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$25.23

Price Target Upside57.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)1.47

Revenue Forecast (FY)HK$43.46B

Bulls Say, Bears Say

Bulls Say

Revenue ReboundA 158% TTM revenue rebound signals recovery from prior declines and strengthening commercial execution. Sustained revenue growth supports scale benefits, funds R&D and commercial expansion, and improves the firm's ability to absorb cost pressure over the next 2–6 months and beyond.

Resilient MarginsNear-50% gross margin with positive net margin reflects product mix and pricing power in pharmaceutical operations. Durable margin levels provide room to reinvest in pipelines and services, supporting profitability stability even if sales mix shifts across segments.

Diversified Business ModelMulti-segment model—manufacturing, distribution, and healthcare services—reduces reliance on any single product or channel. Structural diversification stabilizes cash flows, enables cross-selling, and cushions the firm against shocks in individual therapeutic areas or distribution disruptions.

Bears Say

Weak Cash ConversionLow FCF-to-net-income (~24%) and volatility indicate earnings do not reliably convert to cash. This limits capacity to fund capex, acquisitions, dividends or unexpected needs without raising external financing, raising execution risk if working capital or investments rise.

Moderate LeverageA debt-to-equity near 0.75 with only mid-single-digit ROE implies capital intensity and average returns. Moderate leverage reduces balance sheet flexibility, elevates refinancing and interest risks, and constrains the company's ability to pursue large strategic investments without increasing leverage.

Operating Margin PressureDeclining EBITDA margin and modest EBIT (~7.3%) point to cost or mix headwinds. Persistent margin erosion limits free cash generation and reinvestment capacity, making long-term earnings growth more reliant on structural improvements rather than cyclical revenue gains.

Shanghai Fosun Pharmaceutical (Group) Co News

Fosun Pharma Unit Wins NMPA Nod for Parkinson’s Drug Trial

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical said its subsidiary...

4d ago

Fosun Pharma Wins NMPA Nod for FXR0906 Hypertriglyceridemia Trial

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ). Shanghai Fosun Pharmaceutical’s subsidiary...

13d ago

Fosun Pharma Subsidiary Wins Approval for New Traditional Chinese Medicine Granules

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical said its subsidiary...

29d ago

Fosun Pharma Moves Ahead With Spin-Off Listing of Fosun Adgenvax in Hong Kong

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

1M ago

Fosun Pharma Shareholders Back AGM Resolutions and Final Dividend

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.,...

1M ago

Fosun Pharma Sets Final 2025 Dividend and Withholding Tax Terms for H-Share Investors

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

1M ago

Fosun Pharma Wins NMPA Approval for New Pediatric Use of Luvometinib

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical has announced that...

1M ago

Fosun Pharma Subsidiary Wins China Approval for Broad-Spectrum Levofloxacin Injection

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical has announced that...

2M ago

Fosun Pharma Subsidiary Wins NMPA Acceptance for Innovative TCM Women’s Health Drug

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical announced that the...

3M ago

Fosun Pharma Sets AGM to Approve 2025 Results and New Capital Mandates

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical has called its...

3M ago

Shanghai Fosun downgraded to Hold from Buy at HSBC

HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The...

3y ago

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos...

4y ago

SYNH

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$14.90 and its highest was HK$29.00 in the past 12 months.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$64.43B.

When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 29 days.

How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported HK$0.382 earnings per share for the quarter, beating the consensus estimate of HK$0.376 by HK$0.006.

Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?

According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.45 which represents an annual dividend yield of 2.8%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.41.

How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.

What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.382 in its last earnings report, beating expectations of HK$0.376. Following the earnings report the stock price went up 1.272%.

Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?

Currently, no hedge funds are holding shares in HK:2196

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

Neutral

Fundamentals

Return on Equity

2.80%

Trailing 12-Months

Asset Growth

9.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co (2196) Earnings & Revenues

Historic Earnings Reports

2196 Stock 12 Month Forecast

Average Price Target

HK$25.23

▲(57.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","18":"HK$18","23":"HK$23","28":"HK$28","33":"HK$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.23333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$25.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$18.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18,23,28,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.709,16.039076923076923,17.369153846153846,18.69923076923077,20.029307692307693,21.359384615384617,22.689461538461536,24.01953846153846,25.349615384615383,26.679692307692306,28.00976923076923,29.339846153846153,30.669923076923077,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.709,15.518564102564103,16.328128205128206,17.137692307692305,17.947256410256408,18.75682051282051,19.566384615384614,20.375948717948717,21.18551282051282,21.995076923076923,22.804641025641025,23.61420512820513,24.423769230769228,{"y":25.23333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.709,14.98523076923077,15.261461538461539,15.537692307692307,15.813923076923077,16.090153846153846,16.366384615384614,16.642615384615386,16.918846153846154,17.195076923076925,17.471307692307693,17.74753846153846,18.023769230769233,{"y":18.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.117,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.341,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.247,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.097,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.189,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.813,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.032,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.343,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.827,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.918,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.603,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.695,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.709,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >